Globalization of clinical trials - where are we heading?

Current Clinical Pharmacology

Volumn 8, Issue 2, 2013, Pages 115-123

  George, Melvin ^a   Selvarajan, Sandhiya ^a   Suresh Kumar, S ^a   Dkhar, Steven A ^a   Chandrasekaran, Adithan ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Clinical trials; Emerging countries; Globalization; Trends; WHO ICTRP

Indexed keywords

ARTICLE; CANCER RESEARCH; CHINA; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; GERMANY; HUMAN; INDIA; INTERNET; JAPAN; PREGNANCY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SOUTH KOREA; UNITED STATES; WESTERN EUROPE; WORLD HEALTH ORGANIZATION;

CLINICAL TRIALS AS TOPIC; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HUMANS; INTERNATIONALITY; REGISTRIES; WORLD HEALTH ORGANIZATION;

EID: 84876886454     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884711308020004     Document Type: Article

References (36)

1. The 10 leading causes of death by broad income group-2008. Available at: www. who.int/mediacentre/factsheets/fs310/en/index.html 1 [Accessed November 12, 2011].
2. Geary S. What does the growing prominence of Asia mean forpharmaceutical safety management? Future Med Chem 2010; 10:1503-6.
3. Cost-effective clinical research. Available at: http://www.pharmafocusasia.com/clinical_trials/offshoring_cost_effective_clinical_research.htm [Accessed on November12,2011].
4. Rowland C. Clinical trials seen shifting overseas. Int J Health Serv2004; 343: 555-6.
5. Glickman SW, McHutchison JG, Peterson ED, et al. Ethical andscientific implications of the globalization of clinical research. NEngl J Med 2009; 360: 816-23.
6. Thiers FA, Sinsky AJ, Berndt ER. Trends in the globalization ofclinical trials. Nature reviews: Drug Discov 2008; 7: 13-4.
7. ClinicalTrials. gov. Available at: http://clinicaltrials.gov/ct2/search/advanced [Accessed on November 6, 2011].
8. Sood A, Prasad K, Chhatwani L, et al. Patients' attitudes andpreferences about participation and recruitment strategies inclinical trials. Mayo Clin Proc 2009; 84: 243-7.
9. Printz C. CancerScope. Clinical trials go global. As trialrecruitment expands worldwide, fewer US patients take part. Cancer 2009; 115: 1135-7.
10. Samson K. Unabated increases in trial costs reflect evolvingresearch milieu. Ann Neurol 2009; 65: 9-11.
11. Scoggins JF, Ramsey SD. A national cancer clinical trials systemfor the 21st century: reinvigorating the NCI Cooperative GroupProgram. J Natl Cancer Inst 2010; 102: 1371.
12. Basic principles on global clinical trials. Available at: http://www.pmda.go.jp/operations/notice/2007/file/0928010-e.pdf[Accessed onNovember 9, 2011]
13. Saint RA, Sweeney F. Clinical trials in developing countries: riskor opportunity? Future Med Chem 2009; 1: 1193-5.
14. Annemans L, Cleemput I, Hulstaert F, Simoens S. Stimulatingpharmaceutical innovation in the EU. Expert Rev PharmacoeconOutcomes Res 2011; 11: 235-9.
15. Lambers Heerspink HJ, Dobre D, Hillege HL, Grobbee DE, de ZD. Does the European clinical trials directive really improve clinicaltrial approval time? Br J Clin Pharmacol 2008; 66: 546-50.
16. Mason E. European Commission considers revisions to clinicaltrials directive. J Natl Cancer Inst 2010; 102: 292-7.
17. Neaton JD, Babiker A, Bohnhorst M, et al. Regulatory impedimentsjeopardizing the conduct of clinical trials in Europe funded by theNational Institutes of Health. Clin Trials 2010; 7: 705-18.
18. Sato Y, Koyama K. Clinical research in Japan: past, present andfuture. Keio J Med 2010; 59:104-9.
19. Sinha G. Japan works to shorten "drug lag, " boost trials of newdrugs. J Natl Cancer Inst 2010; 102: 148-51.
20. Alvarenga LS, Martins EN. Biopharmaceutical industry-sponsoredglobal clinical trials in emerging countries. Rev Assoc Med Bras2010; 56: 428-33.
21. Shah JY, Phadtare A, Rajgor D, et al. What leads Indians toparticipate in clinical trials? A meta-analysis of qualitative studies. PLoS One 2010; 5: e10730.
22. Shin SG. South Korea emerges as a major player. BiospectrumResource Guide 2009; 69-70.
23. Cyranoski D. Pharmaceutical futures: made in China? Nature 2008;455: 1168-70.
24. Kircher M. The pharmaceutical industry needs more innovation inbioprocesses. Future Med Chem 2011; 3: 1737-40.
25. Doloresco F, Fominaya C, Schumock GT, et al. Projecting futuredrug expenditures: 2011. Am J Health Syst Pharm 2011; 68: 921-32.
26. Zhang D, Freemantle N, Cheng KK. Are randomized trialsconducted in China or India biased? A comparative empiricalanalysis. J Clin Epidemiol 2011; 64: 90-5.
27. Singh JA. The challenge of discharging research ethics duties inresource-constrained settings. PLoS Med 2011; 8: e1000421.
28. Shah S. Globalization of clinical research by the pharmaceuticalindustry. Int J Health Serv 2003; 33: 29-36.
29. Normile D. The promise and pitfalls of clinical trials overseas. Science 2008; 322: 214-6.
30. de Melo-Martin I, Ho A. Beyond informed consent: the therapeuticmisconception and trust. J Med Ethics 2008; 34: 202-5.
31. de Vries MC, Houtlosser M, Wit JM, et al. Ethical issues at theinterface of clinical care and research practice in pediatric oncology:a narrative review of parents' and physicians' experiences. BMCMed Ethics 2011; 27: 18.
32. Fried E. The therapeutic misconception, beneficence, and respect. Account Res 2001; 8: 331-48.
33. Craven R. Testing times for clinical research. Lancet Neurol 2010;9: 144-5.
34. Gupta YK, Padhy BM. India's growing participation in globalclinical trials. Trends Pharmacol Sci 2011; 32: 327-9.
35. Mgone CS, Makanga M. Fighting HIV/AIDS, tuberculosis and malaria:one world, one partnership. Trop Med Int Health 2010; 15: 973-4.
36. Fillit H, Cummings J, Neumann P, McLaughlin T, SalavtoreP, Leibman C. Novel approaches to incorporating pharmacoeconomicstudies into phase III clinical trials for Alzheimer'sdisease. J Nutr Health Aging 2010; 14: 640-7.